Effects of tafamidis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy

被引：0
作者：
Rettl, R. Rene [1 ]
Duca, F. [1 ]
Binder, C. [1 ]
Capelle, C. [1 ]
Eslam, R. Badr [1 ]
Aschauer, S. [1 ]
Mascherbauer, J. [1 ]
Hengstenberg, C. [1 ]
Bonderman, D. [1 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
49
引用
收藏
页码：8 / 8
页数：1
相关论文
共 50 条
  • [31] Tafamidis (Vyndagel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1590): : 16 - 16
  • [32] Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy
    Psotka, Mitchell A.
    JACC-HEART FAILURE, 2021, 9 (02) : 124 - 126
  • [33] Mortality Among Older Transthyretin Amyloid Cardiomyopathy Patients On Tafamidis
    Batra, Supria
    Patel, Hina
    Govi, Ashley
    Panjrath, Gurusher
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [34] Change in echocardiography in patients with transthyretin amyloid cardiomyopathy with tafamidis treatment
    Morioka, M.
    Takashio, S.
    Fujiyama, H.
    Oike, F.
    Hanatani, S.
    Usuku, H.
    Yamamoto, E.
    Matsushita, K.
    Tsujita, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1764 - 1764
  • [35] EFFECT OF TAFAMIDIS ON RENAL FUNCTION IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN ATTR-ACT
    Sperry, Brett Wesley
    Sultan, Marla B.
    Gundapaneni, Balarama
    Tai, Sandi See
    Witteles, Ronald
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 336 - 336
  • [36] Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
    Li, Benjamin
    Alvir, Jose
    Stewart, Michelle
    CARDIOLOGY AND THERAPY, 2020, 9 (02) : 535 - 540
  • [37] Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
    Benjamin Li
    Jose Alvir
    Michelle Stewart
    Cardiology and Therapy, 2020, 9 : 535 - 540
  • [38] Tafamidis and Incidence of Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy
    Girvin, Zachary P.
    Sweat, Austin O.
    Kochav, Stephanie M.
    Maurer, Mathew S.
    Dizon, Jose
    Wan, Elaine Y.
    Biviano, Angelo
    Garan, Hasan
    Yarmohammadi, Hirad
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2023, 9 (04) : 586 - 587
  • [39] Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
    Elliott, Perry
    Drachman, Brian M.
    Gottlieb, Stephen S.
    Hoffman, James E.
    Hummel, Scott L.
    Lenihan, Daniel J.
    Ebede, Ben
    Gundapaneni, Balarama
    Li, Benjamin
    Sultan, Marla B.
    Shah, Sanjiv J.
    CIRCULATION-HEART FAILURE, 2022, 15 (01) : E008193
  • [40] Five-year Survival With Tafamidis In Patients With Transthyretin Amyloid Cardiomyopathy
    Hoffman, James E.
    Gundapaneni, Balarama
    Sultan, Marla B.
    Elliott, Perry
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S102 - S102
12345